3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Male Urogenital Diseases
1
Lymphatic Metastasis
1
Infiltrating Bladder Urothelial Carcinoma
1
Genital Neoplasms, Male
1
Female Urogenital Diseases
1
Encopresis
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
padeliporfin
5
Abiraterone Acetate
3
Pluvicto
2
Paclitaxel
2
sipuleucel-T
1
rucaparib
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
ixabepilone
1
gallium 68 PSMA-11
1
apalutamide
1
abiraterone
1
Therapeutics
1
Suspensions
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Powders
1
Nivolumab
1
Leuprolide
1
Ipilimumab
1
Imatinib Mesylate
1
EPI-506
1
Chemical Fractionation
1
Biopsy, Needle
1
BAY 86-7548
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
Radiation Dose Hypofractionation
×
Genitourinary
×
Clear all
NCT02319239
2020-10-28
ESKO
Tampere University Hospital
Phase NA
Completed
80 enrolled